A phase 3 multicenter,open‐label,prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

A phase 3 multicenter,open‐label,prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting

Authors:	Larry C Deeb Hélène Dulude Cristina B Guzman Shuyu Zhang Barry J Reiner Claude A Piché Sheetal Pradhan Xiaotian Michelle Zhang

Affiliation:	1. Department of Pediatrics, Florida State University College of Medicine, Tallahassee, Florida;2. Clinical Development, Locemia Solutions, Montreal, Québec, Canada;3. Medical Development, Diabetes Business Unit, Formerly Eli Lilly and Company, Indianapolis, Indiana;4. Statistics, Eli Lilly and Company, Indianapolis, Indiana;5. Clinical Development, Pediatric Endocrine Private Practice, Baltimore, Maryland;6. Global Scientific Communications, Diabetes Business Unit, Eli Lilly Services India Pvt. Ltd., Bangalore, Karnataka, India;7. Medical Development, Diabetes Business Unit, Eli Lilly Canada Inc., Toronto, Ontario, Canada

Abstract:

Keywords:	hypoglycemia nasal glucagon pediatrics type 1 diabetes